Company Overview and News

 
Fitch says Sunshine Holdings new equity issue not enough for ratings upgrade

2018-05-21 lankabusinessonline
May 21, 2018 (LBO) – Fitch Ratings says current ratings of Sunshine Holdings will remain unchanged as the projected fall in net leverage from the proposed private placement will be insufficient to trigger an upgrade.

 
Fitch affirms Singer (Sri Lanka) at ‘A-(lka)’; outlook stable

2018-05-02 lankabusinessonline
Fitch Ratings has affirmed Sri Lanka-based consumerdurables retailer Singer (Sri Lanka) PLC’s National Long-Term Rating at ‘A-(lka)’ with a Stable Outlook. Fitch has also affirmed the National rating on Singer’s outstanding senior unsecured debentures at ‘A-(lka)’. A full list of rating actions is at the end of this commentary.

 
Wildflower Completes Acquisition of Retail and Cultivation Licenses in LA

2018-04-23 globenewswire
VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Wildflower Marijuana Inc. (CSE:SUN) (FWB:RSP) (“Wildflower” or the "Company") has completed the acquisition of multiple California marijuana licenses in the City of Los Angeles including the ownership of a property with a Pre-ICO operating dispensary and cultivation facility. The licenses include medicinal and adult use storefront and delivery, medicinal and adult use cultivation specialty indoor, medicinal and adult use manufacturer level 1 and medical and adult use distributor licenses for both the City of Los Angeles and the State of California.

 
Private Placement Closes

2018-04-18 globenewswire
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Wildflower Marijuana Inc. (CSE:SUN) (FWB:RSP) (“Wildflower” or the "Company") has amended its previously announced financing on March 19, 2018 related to the acquisition of 16 cannabis license in the state of California. The Company will complete a private placement of units (“Units”) at a price of C$1.30 per Unit for aggregate gross proceeds of $4,263,686.

 
Wildflower Re “Brands”

2018-04-09 globenewswire
VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) -- Wildflower Marijuana Inc. (CSE:SUN) (the “Company”) held its Annual and Special Meeting on April 6 where shareholders overwhelming approved to change the Company’s name to “Wildflower Brands Inc.”

 
Fitch affirms Hemas Holdings at AA-(lka); outlook stable

2018-03-28 lankabusinessonline
Fitch Ratings has affirmed Sri Lanka-based conglomerate Hemas Holdings PLC’s (Hemas) National Long-Term Rating at ‘AA-(lka)’ with a Stable Outlook. Fitch has also affirmed the National rating on Hemas’s outstanding senior unsecured debentures at ‘AA-(lka)’.

 
Wildflower’s California Acquisition Moves Forward After Completion of Due Diligence

2018-03-27 globenewswire
VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- Wildflower Marijuana Inc. (CSE:SUN) (FWB:RSP) (“Wildflower” or the "Company") has completed its due diligence and is on schedule for the purchase of multiple California cannabis licenses in the City of Los Angeles. This acquisition includes the ownership of a property with an operating dispensary and cultivation facility. These facilities are licensed to operate through LA’s medical marijuana pre-interim control ordinance (pre-ICO).

 
Eqova Adds 16 Sales Reps To Increase Brand Awareness Among Medical Practitioners & Gives Update on CBD.co Launch

2018-03-20 globenewswire
LAS VEGAS, NV , March 20, 2018 (GLOBE NEWSWIRE) -- Grey Cloak Tech Inc. (OTC: GRCK) announced today that Eqova Life Sciences (Eqova), its medically-focused CBD subsidiary, has added 16 experienced sales reps to its sales force.

 
Fitch Affirms Richard Pieris & Company at ‘A(lka)’; Outlook Stable

2018-02-26 lankabusinessonline
(PRESS RELEASE) Fitch Ratings-Colombo-26 February 2018: Fitch Ratings has affirmed Sri Lanka-based conglomerate Richard Pieris & Company PLC’s (RICH) National Long-Term rating at ‘A(lka)’ with a Stable Outlook.

 
Consumer goods & agri sectors boost Sunshine group profits by 23-pct

2018-02-09 lankabusinessonline
9MFY18 Highlights • Consolidated revenue of Rs.15.6 billion, an increase of 12.4% YoY • PAT amounted to Rs. 1.6 billion, up 23.0% YoY, due to strong Agri and Consumer Goods sector results • Healthcare revenue up 3.3% YoY to Rs. 6.0 billion • Strong growth in Consumer Goods, revenue up 27.4% YoY to Rs 3.8 billion • Agri revenue grew 13.3% YoY to Rs 5.4 billion • EPS grew 63.8% YoY to Rs 5.29

 
Sunshine Holdings invests Rs9mn to partner with investment firm

2018-01-25 lankabusinessonline
Jan 25, 2018 (LBO) – Sunshine Holdings has invested 9 million rupees to partner with Strategic Business Innovator (Pvt) Ltd, an investment firm to be set up in Sri Lanka.

 
Fitch downgrades Sunshine Holdings to A-(lka), outlook stable

2018-01-05 lankabusinessonline
Jan 05, 2018 (LBO) – Fitch Ratings has downgraded Sri Lanka-based Sunshine Holdings PLC’s National Long-Term Rating to ‘A-(lka)’ from ‘A(lka)’. The Outlook is Stable.

 
Tata Global Beverages sells stake in JV for Rs 120 cr

2017-12-28 moneycontrol
Tata Global Beverages (TGBL) has sold its stake in joint venture firm Estate Management Services Private Limited (EMSPL) for a consideration of Rs 120 crore.

 
Tata Global Beverages sells stake in JV for ₹120 cr

2017-12-28 thehindubusinessline
Tata Global Beverages (TGBL) has sold its stake in joint venture firm Estate Management Services Private Limited (EMSPL) for a consideration of ₹120 crore.

 
Tata Global Beverages sells stake in joint venture for Rs120 crore

2017-12-28 livemint
New Delhi: Tata Global Beverages (TGBL) has sold its stake in joint venture firm Estate Management Services Private Limited (EMSPL) for a consideration of Rs120 crore.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...